Opioid-induced neurotoxicity

Canadian Family Physician

Volumn 53, Issue 3, 2007, Pages 426-427

  Gallagher, Romayne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; LACTULOSE; LORAZEPAM; LOXAPINE; MORPHINE; OPIATE; STEROID;

AGED; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONFUSION; CONSTIPATION; DROWSINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MALE; NEUROTOXICITY; SHORT SURVEY; SOMNOLENCE;

AGED, 80 AND OVER; ANALGESICS, OPIOID; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FATAL OUTCOME; HUMANS; MALE; MORPHINE; NEUROTOXICITY SYNDROMES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 34047211558     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. Jennings AL, Davies AN, Higgins JPT, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001;(4):CD002006.
2. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001;21(2):144-50.
3. Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother 2004;18(4):17-30.
4. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28(5):497-504.
5. Gallagher R. An approach to dyspnea in advanced disease. Can Fam Physician 2003;49:1611-6.
6. Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging 2003;20(1):23-57.